US$ 26.36
astria therapeutics glp-1 receptor agonist weight management diabetes treatments Clinical of Regain and Cardiometabolic Consequences After Discontinuation of GLP‐1 Agonists - Shah - 2026 - Diabetes, Obesity and Metabolism astria therapeutics glp-1 receptor agonist
Description
Eur J Heart Fail

Network meta-analyses demonstrate a progressive efficacy gradient: GLP-1 monotherapy achieves approximately 7 kg weight reduction, dual agonists reach 11 kg, while triple agonists achieve up to 24 kg weight loss at 52 weeks [77]

doi: 10.1074/jbc.M500540200 [DOI] [PubMed] [Google Scholar] 115

Dev Dyn

The total dose remains the same, but the pharmacokinetic profile changes

All data sources are cited in the reference list.
